<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02658240</url>
  </required_header>
  <id_info>
    <org_study_id>STU 122015-022</org_study_id>
    <nct_id>NCT02658240</nct_id>
  </id_info>
  <brief_title>Ultrasound-guided Fascia Iliaca Compartment Block Versus Periarticular Infiltration</brief_title>
  <official_title>Ultrasound-guided Fascia Iliaca Compartment Block Versus Periarticular Infiltration for Pain Management After Total Hip Arthroplasty: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, controlled, observer-blinded study clinical trial was designed to evaluate
      ultrasound-guided fascia iliaca compartment block with ropivacaine and periarticular
      infiltration with ropivacaine for postoperative pain management after total hip arthroplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite substantial advances in our understanding of the pathophysiology of pain and
      availability of newer analgesic techniques, postoperative pain is not always effectively
      treated. Optimal pain management technique balances pain relief with concerns about safety
      and adverse effects associated with analgesic techniques. Currently, postoperative pain is
      commonly treated with systemic opioids, which are associated with numerous adverse effects
      including nausea and vomiting, dizziness, drowsiness, pruritus, urinary retention, and
      respiratory depression. Use of regional and local anesthesia has been shown to reduce opioid
      requirements and opioid-related side effects.

      Patients undergoing total hip arthroplasty (THA) (n=60) at Parkland and UT Southwestern
      Medical Center Hospitals will be randomized into one of two groups to receive either
      ultrasound-guided fascia iliaca compartment block (FICB) with ropivacaine 300 mg and 0.5 mg
      epinephrine (Group 1) or periarticular infiltration ropivacaine 300 mg and 0.5 mg epinephrine
      total (Group 2) for postoperative pain management. The remaining aspect of perioperative
      care, including the anesthetic technique (i.e., spinal anesthetic), pre- and postoperative
      care will be standardized and will be similar for all patients. The duration of the
      involvement in the study will be until 48 hours postoperatively.

      Patients in Group 1 will receive ultrasound-guided FICB after surgery. Patients in Group 2
      will receive ropivacaine via periarticular infiltration prior to closing the incision.

      The postoperative analgesia will be documented using the visual analog score (0=no pain,
      10=worst pain). In addition, total opioid dose over the 48-h study period will be documented.
      Postoperative nausea will be measured using a categorical scoring system (none=0, mild=1,
      moderate=2, severe=3) and episodes of vomiting will be documented. Rescue antiemetics will be
      given to any patient who complains of nausea and/or vomiting. All variables will be assessed
      at 2, 6, 12, 24, and 48 hours, postoperatively by an investigator blinded to group
      allocation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 5, 2016</start_date>
  <completion_date type="Actual">December 16, 2017</completion_date>
  <primary_completion_date type="Actual">November 13, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Pain Score at Resting</measure>
    <time_frame>Postoperative 48 hours</time_frame>
    <description>The Visual Analog Pain Score (VAS) at resting on the scale of 10 (0= No pain, 10= Worst pain) at 48 hours postoperatively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Pain Score With Movement</measure>
    <time_frame>Postoperative 48 hours</time_frame>
    <description>The Visual Analog Pain Score (VAS) with movement on the scale of 10 (0= No pain, 10= Worst pain) at 48 hours postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oral Morphine Equivalents of Postoperative Opioid Requirements for 48 Hours</measure>
    <time_frame>Postoperative 48 hours</time_frame>
    <description>Total amounts of postoperative opioid requirements for 48 hours postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time to Ambulation</measure>
    <time_frame>Postoperative 48 hours</time_frame>
    <description>The time to ambulation during 48 hours postoperative period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Compartment Block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fascia iliaca compartment block (FICB) with ropivacaine and epinephrine after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infiltration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Periarticular infiltration with ropivacaine and epinephrine prior to closing the incision</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL</description>
    <arm_group_label>Compartment Block</arm_group_label>
    <arm_group_label>Infiltration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>0.5 mg epinephrine</description>
    <arm_group_label>Compartment Block</arm_group_label>
    <arm_group_label>Infiltration</arm_group_label>
    <other_name>Adrenaline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female ASA physical status 1-3 scheduled for total hip arthroplasty

          -  Age 18-80 years old

          -  Able to participate personally or by legal representative in informed consent in
             English or Spanish

        Exclusion Criteria:

          -  History of relevant drug allergy

          -  Age less than 18 or greater than 80 years

          -  Chronic opioid use or drug abuse

          -  Significant psychiatric disturbance

          -  Inability to understand the study protocol

          -  Refusal to provide written consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irina Gasanova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UTSW Parkland Health Hospital System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>January 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2016</study_first_posted>
  <results_first_submitted>October 3, 2018</results_first_submitted>
  <results_first_submitted_qc>November 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 29, 2018</results_first_posted>
  <last_update_submitted>November 26, 2018</last_update_submitted>
  <last_update_submitted_qc>November 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Irina Gasanova</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Nerve block</keyword>
  <keyword>Periarticular infiltration</keyword>
  <keyword>Ropivacaine</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT02658240/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Compartment Block</title>
          <description>Fascia iliaca compartment block (FICB) with ropivacaine and epinephrine after surgery
Ropivacaine: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
Epinephrine: 0.5 mg epinephrine</description>
        </group>
        <group group_id="P2">
          <title>Infiltration</title>
          <description>Periarticular infiltration with ropivacaine and epinephrine prior to closing the incision
Ropivacaine: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
Epinephrine: 0.5 mg epinephrine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Compartment Block</title>
          <description>Fascia iliaca compartment block (FICB) with ropivacaine and epinephrine after surgery
Ropivacaine: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
Epinephrine: 0.5 mg epinephrine</description>
        </group>
        <group group_id="B2">
          <title>Infiltration</title>
          <description>Periarticular infiltration with ropivacaine and epinephrine prior to closing the incision
Ropivacaine: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
Epinephrine: 0.5 mg epinephrine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="13.6"/>
                    <measurement group_id="B2" value="59.0" spread="11.2"/>
                    <measurement group_id="B3" value="57.6" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative Pain Score at Rest</title>
          <description>The Visual Analog Pain Score (VAS) on the scale of 10 (0= No pain, 10= Worst pain) at preoperatively</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B2" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="B3" value="4" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative Pain Score with Cough</title>
          <description>The Visual Analog Pain Score (VAS) with cough on the scale of 10 (0= No pain, 10= Worst pain) preoperatively</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="B2" value="8" lower_limit="7" upper_limit="10"/>
                    <measurement group_id="B3" value="8" lower_limit="6.75" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Pain Score at Resting</title>
        <description>The Visual Analog Pain Score (VAS) at resting on the scale of 10 (0= No pain, 10= Worst pain) at 48 hours postoperatively</description>
        <time_frame>Postoperative 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Compartment Block</title>
            <description>Fascia iliaca compartment block (FICB) with ropivacaine and epinephrine after surgery
Ropivacaine: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
Epinephrine: 0.5 mg epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Infiltration</title>
            <description>Periarticular infiltration with ropivacaine and epinephrine prior to closing the incision
Ropivacaine: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
Epinephrine: 0.5 mg epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Pain Score at Resting</title>
          <description>The Visual Analog Pain Score (VAS) at resting on the scale of 10 (0= No pain, 10= Worst pain) at 48 hours postoperatively</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The study was powered to detect a mean difference of 1.5 in pain scores in favor of patients undergoing SFICB procedure assuming a standard deviation of 2.5. With a two sided alpha level of 0.05, a total of 52 patients would be needed to have 80% power using a repeated measures ANOVA F test with 6 observations on each subject. Correlation on the repeat observations was assumed to be 0.5. Assuming a 14% loss to follow-up, 60 patients were enrolled at 1:1 ratio.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Pain Score With Movement</title>
        <description>The Visual Analog Pain Score (VAS) with movement on the scale of 10 (0= No pain, 10= Worst pain) at 48 hours postoperatively</description>
        <time_frame>Postoperative 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Compartment Block</title>
            <description>Fascia iliaca compartment block (FICB) with ropivacaine and epinephrine after surgery
Ropivacaine: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
Epinephrine: 0.5 mg epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Infiltration</title>
            <description>Periarticular infiltration with ropivacaine and epinephrine prior to closing the incision
Ropivacaine: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
Epinephrine: 0.5 mg epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Pain Score With Movement</title>
          <description>The Visual Analog Pain Score (VAS) with movement on the scale of 10 (0= No pain, 10= Worst pain) at 48 hours postoperatively</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Morphine Equivalents of Postoperative Opioid Requirements for 48 Hours</title>
        <description>Total amounts of postoperative opioid requirements for 48 hours postoperatively</description>
        <time_frame>Postoperative 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Compartment Block</title>
            <description>Fascia iliaca compartment block (FICB) with ropivacaine and epinephrine after surgery
Ropivacaine: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
Epinephrine: 0.5 mg epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Infiltration</title>
            <description>Periarticular infiltration with ropivacaine and epinephrine prior to closing the incision
Ropivacaine: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
Epinephrine: 0.5 mg epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Morphine Equivalents of Postoperative Opioid Requirements for 48 Hours</title>
          <description>Total amounts of postoperative opioid requirements for 48 hours postoperatively</description>
          <units>Oral Morphine Equivalent (mg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.0" spread="29.5"/>
                    <measurement group_id="O2" value="115.6" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.149</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time to Ambulation</title>
        <description>The time to ambulation during 48 hours postoperative period</description>
        <time_frame>Postoperative 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Compartment Block</title>
            <description>Fascia iliaca compartment block (FICB) with ropivacaine and epinephrine after surgery
Ropivacaine: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
Epinephrine: 0.5 mg epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Infiltration</title>
            <description>Periarticular infiltration with ropivacaine and epinephrine prior to closing the incision
Ropivacaine: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
Epinephrine: 0.5 mg epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>The Time to Ambulation</title>
          <description>The time to ambulation during 48 hours postoperative period</description>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" lower_limit="19" upper_limit="23.5"/>
                    <measurement group_id="O2" value="22" lower_limit="19.5" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.584</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected during 48 hours postoperatively.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Compartment Block</title>
          <description>Fascia iliaca compartment block (FICB) with ropivacaine and epinephrine after surgery
Ropivacaine: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
Epinephrine: 0.5 mg epinephrine</description>
        </group>
        <group group_id="E2">
          <title>Infiltration</title>
          <description>Periarticular infiltration with ropivacaine and epinephrine prior to closing the incision
Ropivacaine: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
Epinephrine: 0.5 mg epinephrine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Irina Gasanova</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>4694191997</phone>
      <email>Irina.Gasanova@UTSouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

